Optimising stroke prevention in patients with atrial fibrillation: Application of the GRASP-AF audit tool in a UK general practice cohort

British Journal of General Practice

Volumn 65, Issue 630, 2015, Pages e16-e23

  Shantsila, Eduard ^a   Wolff, Andreas ^b   Lip, Gregory Y H ^a   Lane, Deirdre A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Whinfield Medical Practice   (United Kingdom)

Author keywords

Antithrombotic therapy; Atrial fibrillation; General practice; Mortality; Risk stratification; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIAC PATIENT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENERAL PRACTICE; GUIDANCE ON RISK ASSESSMENT AND STROKE PREVENTION IN THE ATRIAL FIBRILLATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; NEUROLOGIC DISEASE ASSESSMENT; OBSERVATIONAL STUDY; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; ATRIAL FIBRILLATION; COMPLICATION; HEALTH SERVICE; MIDDLE AGED; MORTALITY; PREVENTION AND CONTROL; PROCEDURES; STATISTICS AND NUMERICAL DATA; STROKE; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; GENERAL PRACTICE; HEALTH SERVICES MISUSE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL ANALYSIS; UNITED KINGDOM;

EID: 84920054245     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp15X683113     Document Type: Article

References (22)

1. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747.
2. National Clinical Guideline Centre. Atrial fibrillation: the management of atrial fibrillation. National Institute for Health and Care Excellence, 2014. http://www.nice.org.uk/guidance/CG180 (accessed 3 Nov 2014).
3. You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-575S.
4. Gage B Gage BF, Waterman AD, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
5. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013; 99: 1166-1172.
6. Kakkar AK, Mueller I, Bassand JP, et al. GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8: e63479.
7. Nieuwlaat R, Capucci A, Lip GY, et al. Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
8. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart 2013; 99: 127-132.
9. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.
10. Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract 2012; DOI: 10.3399/bjgp12X656856.
11. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2011; 8: 602-606.
12. Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
13. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
14. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
15. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5: 319-326.
16. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
17. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk - treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011; 97: 2046-2050.
18. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-1506.
19. Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORPAF) Pilot General Registry. Europace 2014; 16: 308-319.
20. LaHaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
21. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 2001; 323: 1218-1222.
22. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. Patient preference-based treatment thresholds and recommendations: a comparison of decisionanalytic modeling with the probability-tradeoff technique. Med Decis Making 2000; 20: 394-403.